Our Research

Our Research

>> Research Departments
>> Find Clinical Trials
>> Our Publications
>> Our Research Collaborations

Contact Details

  Street address:
Level 11, KGV Building
Missenden Road
Postal address:
Post Office Box M30
Missenden Road NSW 2050

Phone: (02) 9515-6111
Fax: (02) 9515-9610

Online Feedback


Our Research

Currently (last 12 months) funded research studies include:

  1. AMS# Alemtuzumab MS Safety Systems (AMSSS). A study developing systems to minimize the risk on MS treatment with alemtuzumab. An Australia New Zealand Clinical Trials Registry, a World Health Organistion International Clinical trials Registry Platform Primary Registry. Funded by Sydney Local health District and Genzyme, Sanofi.
  2. TOPAZ Study - A long term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) - Sanofi.
  3. LEMTRADA PASS Study - A prospective, multicenter, observational post-authorisation safety study to evaluate the long term safety profile of Lemtrada (Alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis. - Sanofi.
  4. MSBase. An International Registry dedicated to the evaluating outcomes data in Multiple Sclerosis (MS) and linking MS Researchers. Sponsored by The MSBase Foundation LTD sponsored by various pharma companies.  
  5. ESTEEM Study: An Observational Study to collect safety information and drug utilization of dimethyl fumarate in routine treatment of MS patients. Sponsored by Biogen Idec. 
  6. Bone health in fascioscapulohumeral muscular dystrophy. A cross sectional study of bone density in adult patients with FSHD in the USA and Australia. Sponsored by FSHD Global Research Foundation. 
  7. DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease (PD) – a Global Observational Study Evaluating Long-Term Effectiveness.
  8. TOZ-CLO6 Study. Multi-centre, open label study to evaluate the safety and tolerability of Tozadenent as adjunctive therapy in levodopa treated Parkinson’s patients experiencing end-of-dose ‘wearing-off’ effects.
  9. CSLCT-IVIG-11-74 Stusy evaluating the occurence of aseptic menigitis syndrome (AMS) in an adult population > 18 years of age treated with Intragam 10 NF.
  10. A whole genome sequencing collaborative study of fascio-scapular-humeral dystrophy (FSHD) and its phenocopies with Professors Nicholson, Corbett, Cowley and Kumar.

Current clinical studies (Assoc. Prof Aggarwal):

  1. 2012-present A comparative open label study comparing the efficacy of structured physiotherapy vs non structured physiotherapy in reducing post-stroke spasticity related shoulder pain in patients treated with Botulinum toxin A. RPAH Spasticity Clinic.
  2. 2014 – present An International, Multicenter, Observational, Prospective, Longitudinal Cohort Study To Assess The Impact Of Integrated Spasticity Management Including Repeated Bot-A Injections On Patient-Centred Goal Attainment In Adult Subjects Suffering From Upper Limb Spasticity – ULIS III. RPAH Spasticity Clinic.  
  3. Prevalence of Biochemical and Hormonal Abnormalities in Chronic Pain Patients RPAH Spasticity Clinic. 
  4. 2015 – present: Rehabilitation Outcomes of the Dys-executive Syndrome of Thalamic Stroke. Metro Rehab Hospital.    
  5. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type-I. RPAH Pain Clinic.

Research Staff


  • Professor Alastair Corbett. (Stroke, neuromuscular and neuroimmunology)
  • Dr Michael Hayes. (Movement disorders) 
  • Assoc. Prof Stephen Reddel. (Neuromuscular and neuroimmunology) 
  • Dr Todd Hardy. (Neuroimmunlogy) 
  • Dr Carrie Hurelbrink. (Movement disorders) 
  • Professor Con Yiannikas (Neuroimmunology, neuromuscular)

Study Coordinators:

  • Rosie Portley, RN (Stroke, movement disorders, neuromuscular, neuroimmunology)
  • Alison Wilson, Neurosciences CNC (Stroke data and neuroimmunology inpatient support)

Publications and Presentations

Publication Details:
  1. Min-Xia Wang M-X, Spring P, Pollard J, Spies J. Atypical CIDP or CMT in the elderly? A case report. Journal of Neuromuscular Diseases; 3, no. s1, p S79, 2016.
  2. Tawil R, Mah JK, Baker S, Wagner KR, Ryan MM; Sydney Workshop Participants.Clinical practice considerations in facioscapulohumeral muscular dystrophy, Sydney, Australia, 21 September 2015. Neuromuscul Disord. 2016 Jul;26(7):462-71. doi: 10.1016/j.nmd.2016.03.007. Epub 2016 Apr 25. PubMed PMID: 27185458. 
  3. Zekry O, Gibson S , Aggarwal A. Sub-anaesthetic Subcutaneous Ketamine Infusion Therapy in the Treatment of Chronic Non-Malignant Pain. J. of Pain & Palliative Care Pharmacotherapy Apr 2016: 1-8. 
  4. Pirapakaran K, Aggarwal A. The Use of Low-Dose Sodium Valproate in the Management of Neuropathic Pain: Illustrative Case Series. Internal Medicine Journal July 2016
  5. Albulym OM, Kennerson ML, Harms MB, Drew AP, Siddell AH, Auer-Grumbach M, Pestronk A, Connolly A, Baloh RH, Zuchner S, Reddel SW, Nicholson GA.  MORC2 mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs. Ann Neurol. 20 1Mar;79(3):419- 27.
  6. Garg N, Yiannikas C, Hardy TA, Belaya K, Cheung J, Beeson D, Reddel SW. Late presentations of congenital myasthenic syndromes: How many do we miss? Muscle Nerve. 2016 Oct;54(4):721-7.
  7. Stoll M, Teoh H, Lee J, Reddel S, Zhu Y, Buckley M, Sampaio H, Roscioli T, Farrar M, Nicholson G. Novel motor phenotypes in patients with VRK1 mutations without pontocerebellar hypoplasia. Neurology. 2016 Jul 5;87(1):65-70.
  8. Brewer MH, Chaudhry R, Qi J, Kidambi A, Drew AP, Menezes MP, Ryan MM, Farrar MA, Mowat D, Subramanian GM, Young HK, Zuchner S, Reddel SW, Nicholson  GA,  Kennerson ML. Whole Genome Sequencing Identifies a 78 kb Insertion  from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3.  PLoS Genet. 2016 Jul20;12(7):e1006177.
  9. Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG.  Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurol. 2016 Aug;15(9):967-81.
  10. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia  C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016 Aug 11;375(6):511-22.
  11. Hardy TA, Lee AW, Yiannikas C, Chen CS, Reddel SW. Extensive Postradiation Ocular and Diffuse Cranial Neuromyotonia Mimicking Myasthenia Gravis. Neurologist. 20 Sep;21(5):79-82.
  12. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016 Nov 8;87(19):1985-1992.
  13. O'Grady GL, Best HA, Sztal TE, Schartner V, Sanjuan-Vazquez M, Donkervoort S, Abath Neto O, Sutton RB, Ilkovski B, Romero NB, Stojkovic T, Dastgir J, Waddell  LB, Boland A, Hu Y, Williams C, Ruparelia AA, Maisonobe T, Peduto AJ, Reddel SW, Lek M, Tukiainen T, Cummings BB, Joshi H, Nectoux J, Brammah S, Deleuze JF, Ing VO, Ramm G, Ardicli D, Nowak KJ, Talim B, Topaloglu H, Laing NG, North KN, MacArthur DG, Friant S, Clarke NF, 
  14. Bryson-Richardson RJ, Bönnemann CG, Laporte J, Cooper ST. Variants in the Oxidoreductase PYROXD1 Cause Early-Onset Myopathy with Internalized Nuclei and Myofibrillar Disorganization. Am J Hum Genet. 2016 Nov 3;99(5):1086-1105.
  15. Dyer WB, Tan JC, Day T, Kiers L, Kiernan MC, Yiannikas C, Reddel S, Ng K, Mondy P, Dennington PM, Dean MM, Trist HM, Dos Remedios C, Hogarth PM, Vucic S, Irving DO. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic  inflammatory demyelinating polyradiculoneuropathy. Brain Behav. 2016  Jul 14;6(10):e00516.
  16. Anine H. Stam, Parul H. Kothari, Aisha Shaikh, Andreas Gschwendter, Joanna C. Jen, Suzanne Hodgkinson, Todd A. Hardy, Michael Hayes, Peter A. Kempster, Katya E. Kotschet, Ingeborg M. Bajema, Sjoerd G. van Duinen, Marion L. C. Maat-Schieman, Paulus T. V. M. de Jong, Marc D. de Smet, Didi de Wolff-Rouendaal, Greet Dijkman, Nadine Pelzer, Grant R. Kolar, Robert E. Schmidt, JoAnne Lacey, Daniel Joseph, David R. Fintak, M.Gilbert Grand, Elizabeth M. Brunt, Helen Liapis, Rula A. Hajj-Ali, Mark C. Kruit,Mark A. van Buchem, Martin Dichgans, Rune R. Frants, Arn M. J. M. van denMaagdenberg, Joost Haan, Robert W. Baloh, John P. Atkinson,Gisela M. Terwindt and Michel D. Ferrari. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain 2016: 139; 2909–2922
  17. Chagarlamudi H, Corbett A, Stoll M, Bibat G, Grosmann C, Matichak Stock C,Stinson N, Shapiro J, Wagner KR. Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study. Muscle Nerve. 2017 Feb 18. doi: 10.1002/mus.25619. [Epub ahead of print] PubMed PMID: 28214289.
  18. Price MA, Barghout V, Benveniste O, Christopher-Stine L, Corbett A, de Visser M, Hilton-Jones D, Kissel JT, Lloyd TE, Lundberg IE, Mastaglia F, Mozaffar T, Needham M, Schmidt J, Sivakumar K, DeMuro C, Tseng BS. Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. J Neuromuscul Dis. 2016 Mar 3;3(1):67-75. PubMed PMID: 27854208; PubMed Central PMCID: PMC5271419.
  19. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS; SAVE Investigators and Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med. 2016 Sep 8;375(10):919-31. doi: 10.1056/NEJMoa1606599. Epub 2016 Aug 28. PubMed PMID: 27571048.
  20. Tawil R, Mah JK, Baker S, Wagner KR, Ryan MM; Sydney Workshop Participants. Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscul Disord. 2016 Jul;26(7):462-71.  doi: 10.1016/j.nmd.2016.03.007. Epub 2016 Apr 25. PubMed PMID: 27185458.
  21. Ghaoui R, Cooper ST, Lek M, Jones K, Corbett A, Reddel SW, Needham M, Liang C, Waddell LB, Nicholson G, O'Grady G, Kaur S, Ong R, Davis M, Sue CM, Laing NG, North KN, MacArthur DG, Clarke NF. Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons Learned. JAMA Neurol. 2015 Dec;72(12):1424-32. doi: 10.1001/jamaneurol.2015.2274. PubMed PMID: 26436962.
  22. Diffusivity in multiple sclerosis lesions: At the cutting edge?Klistorner A, Wang C, Fofanova V, Barnett MH, Yiannikas C, Parratt J, You Y, Graham SL. Neuroimage Clin. 2016 Jul 5;12:219-26.
  23. Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. Geevasinga N, Menon P, Scherman DB, Simon N, Yiannikas C, Henderson RD, Kiernan MC, Vucic S. Neurology. 2016 Aug 16;87(7):684-90
  24. Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. Graham EC, You Y, Yiannikas C, Garrick R, Parratt J, Barnett MH, Klistorner A. Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2311-7.
  25. Multifocal Neuropathy presenting as pseudodystonia. Nidhi Garg, MBBS (Hons), FRACP,1 Robert N.S. Heard, MD, FRCP, FRACP,2 Lynette Kiers, MBBS, FRACP,3 Richard Gerraty, MD, FRACP,4 Con Yiannikas, FRACP Movement Disorders Clinical PracticeVolume 4, Issue 1, 11 MAR 2016
  26. Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study.Klistorner A, Wang C, Yiannikas C, Graham SL, Parratt J, Barnett MH.PLoS One. 2016 Feb 22;11(2):
  27. Cortical contributions to the flail leg syndrome: Pathophysiological insights.Menon P, Geevasinga N, Yiannikas C, Kiernan MC, Vucic S. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):389-96.
  28. Mutations in HSPB8 causing a new phenotype of distal myopathy and motor neuropathy. Ghaoui R, Palmio J, Brewer J, Lek M, Needham M, Evilä A, Hackman P, Jonson PH, Penttilä S, Vihola A, Huovinen S, Lindfors M, Davis RL, Waddell L, Kaur S, Yiannikas C, North K, Clarke N, MacArthur DG, Sue CM, Udd B. Neurology. 2016 Jan 26;86(4):391-8
  29. Expanding the phenotypic associations of globular glial tau subtypes. Burrell JR, Forrest S, Bak TH, Hodges JR, Halliday GM, Kril JJ. Alzheimers Dement (Amst). 2016 Apr 8;4:6-13. doi: 10.1016/j.dadm.2016.03.006. eCollection 2016. PMID: 27489873.
  30. The neural correlates of auditory and visuospatial span in logopenic progressive aphasia and Alzheimer's disease. Foxe D, Leyton CE, Hodges JR, Burrell JR, Irish M, Piguet O. Cortex. 2016 Oct;83:39-50. doi: 10.1016/j.cortex.2016.07.003. Epub 2016 Jul 15. PMID: 27474916.
  31. Syntactic comprehension deficits across the FTD-ALS continuum. Kamminga J, Leslie FV, Hsieh S, Caga J, Mioshi E, Hornberger M, Ballard KJ, Kiernan MC, Hodges JR, Burrell JR. Neurobiol Aging. 2016 May;41:11-8. doi: 10.1016/j.neurobiolaging.2016.02.002. Epub 2016 Feb 11. PMID: 27103514.
  32. The frontotemporal dementia-motor neuron disease continuum. Burrell JR, Halliday GM, Kril JJ, Ittner LM, Götz J, Kiernan MC, Hodges JR. Lancet. 2016 Aug 27;388(10047):919-31. doi: 10.1016/S0140-6736(16)00737-6. Epub 2016 Mar 14. Review. PMID:26987909
  33. Cognitive and Behavioral Symptoms in ALSFTD: Detection, Differentiation, and Progression.
    Hsieh S, Caga J, Leslie FV, Shibata M, Daveson N, Foxe D, Ramsey E, Lillo P, Ahmed RM, Devenney E, Burrell JR, Hodges JR, Kiernan MC, Mioshi E. J Geriatr Psychiatry Neurol. 2016 Jan;29(1):3-10. doi: 10.1177/0891988715598232. Epub 2015 Aug 6. PMID: 26251110
  34. Motor function and behaviour across the ALS-FTD spectrum. De Silva D, Hsieh S, Caga J, Leslie FV, Kiernan MC, Hodges JR, Mioshi E, Burrell JR. Acta Neurol Scand. 2016 May;133(5):367-72. doi: 10.1111/ane.12471. Epub 2015 Jul 30. PMID: 26223148
  35. Dissociation of Structural and Functional Integrities of the Motor System in Amyotrophic LateralSclerosis and Behavioral-Variant Frontotemporal Dementia. Bae JS1,2, Ferguson M2,3, Tan R2, Mioshi E4, Simon N2, Burrell J2, Vucic S5, Hodges JR2,3, Kiernan MC6, Hornberger M7. J Clin Neurol. 2016 Apr;12(2):209-17. doi: 10.3988/jcn.2016.12.2.209. Epub 2016 Feb 26.

Book Chapters:
  1. 10 Papers the World Forgot: A Critical Analysis of Scientific Progress in GBS. Stephen W. Reddel SW, Hardy TA and Blum S. In: GBS100: Celebrating a century of progress in Guillain-Barré syndrome. Editors Hugh J Willison and John A Goodfellow. ISBN: 978-0-9975103-0-0. Peripheral Nerve Society Press, La Jolla, 2016: pp 34-41.

  • Associate Professor Arun Aggarwal: National 3, International 1
  • Associate Professor Stephen Reddel: National 5+, International 2 
  • Dr Michael Hayes: National 2 
  • Dr Todd Hardy: National 2, International 1

Contact details for department

Head of Department: Dr Michael Hayes

Department/Unit: Neurosciences
Concord Hospital
Hospital Road
Concord NSW 2139
Telephone: (02) 9767 6416
Facsimile: (02) 9767 7807
Web: www.slhd.nsw.gov.au/research/
Email: michael.hayes@health.nsw.gov.au